Regarding recommending and/or purchasing XALIVA for my business, I’m Extremely Likely because we currently use rapid marijuana drug tests and are always looking for new options at reasonable prices. I would be Extremely Interested in learning more about XALIVA because this is an appealing option that would serve our purposes of curbing marijuana use at least on and during workdays.
Working at RICOVR
Our Mission
Revolutionize point-of-care diagnostics with our breakthrough technology by developing accurate and rapid testing. Increasing access will ensure a safer workplace for both employees and employers, advancing our healthcare industry.
Would you like to join us?
Working at RICOVR
We are the creator of the XALIVA® rapid diagnostics platform that provides high-quality, cost-effective, and rapid results for employers using only a small amount of saliva. The testing platform leverages the first truly portable nanoparticle detection technology, allowing for fast, non-invasive point-of-care diagnostics.
With the collaboration of industry experts, the company’s platform is versatile and expanding into new point-of-care diagnostics beyond drug testing, such as infectious disease, maternal health, and cancer detection applications.
Hear what our team have
to say about working here
The industry that I work in is a very dangerous one, so being high on the job puts others at extreme risk of injury or even death. I personally suspect several people of using marijuana on the job and would like to see more on-the-job testing and feel that this product would be worth the cost and would help keep our employees safe.
Sam T
Safety Officer, Manufacturing company
Ricovr Healthcare is a leading healthcare technology company
based in Princeton, New Jersey.
Our growing RICOVR team is building and delivering breakthrough medical technology, and guided by a distinguished advisory board. Our leadership team includes experts across the medical device industry to help transform point-of-care diagnostics and modernize our testing industry.
Subscribe to
our newsletter
